ARCAGY/ GINECO GROUP
65
6
13
45
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
5 terminated/withdrawn out of 65 trials
90.0%
+3.5% vs industry average
18%
12 trials in Phase 3/4
2%
1 of 45 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (65)
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
Role: collaborator
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Role: collaborator
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Role: lead
Genomic BRCA and Extensive ovArian Cancer Testing
Role: lead
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Role: lead
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
Role: lead
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Role: lead
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Role: lead
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Role: lead
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
Role: lead
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Role: lead
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
Role: collaborator
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Role: collaborator
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
Role: lead
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Role: collaborator
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
Role: lead
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
Role: collaborator
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
Role: lead
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
Role: collaborator
NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
Role: lead